Printer Friendly

Safety and efficacy of rennin-angiotensin system inhibitors in heart failure with preserved ejection fraction.

Background

Heart failure with preserved left ventricular ejection fraction [HF-PEF] is a clinically heterogeneous syndrome. It refers to a clinical syndrome in which patients have symptoms and signs of HF, normal or near normal left ventricular systolic function, and evidence of diastolic dysfunction (abnormal left ventricular filling and elevated filling pressures) [1,2]. Among patients with HF, as many as 40 to 60 percent have a normal or near normal left ventricular ejection fraction (LVEF) [1, 3-6]. It's prevalence tends to be higher in women and in older patients with hypertension, atrial fibrillation, or both [J1-3]. Diastolic dysfunction has initially been held as the single pathophysiological abnormality behind this syndrome [J4,20]. However, several different underlying mechanisms are operative among different patient subgroups [J21]. The prognosis of patients with HF-PEF is less well defined than in those with systolic HF. Data from the Framingham Heart Study, the V-HeFT trials, and several observational series revealed varying results [6-12]. In addition, the data are not clear on whether the long-term prognosis differs between diastolic and systolic HF [13].

Renin angiotensin system inhibitors (RASIs), including angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB), play an important role in the treatment of the disease processes that underlie the development of diastolic heart failure, namely, hypertension, coronary artery disease and diabetes. RASIs are beneficial in hypertensive heart disease and by reducing systemic pressure, they cause regression of left ventricular hypertrophy (LVH) and a gradual improvement in diastolic function [14,15]. Also, RASIs have been shown to prevent progression of diastolic dysfunction in patients with mixed systolic and diastolic HF [16]. However, the trials of rennin-angiotensin system inhibitors (RASIs) in patients with HF-PEF have yielded mixed results. We performed a meta-analysis of these trials to evaluate the efficacy and safety of RASIs in heart failure with preserved ejection fraction patients.

Methods

We performed this review in accordance with the Quality of Reporting of Meta-analysis (QUOROM) statement and the Consolidated Standards of Reporting Trials (CONSORT) Group recommendations [17]. A protocol was prospectively developed, detailing the objectives, criteria for study selection and approach to assessing the study quality, primary outcome and methodology.

Literature search: We performed a computerized search to identify all relevant studies published in English-language through July 2010 in EMBASE, CINAHL, Pub Med, and Cochrane database. The key words used for search were: congestive heart failure, chronic heart failure, heart failure, left ventricular systolic dysfunction, Angiotensin converting enzyme inhibitors, angiotensin- II receptor blockers, angiotensin receptor blockers, combination angiotensin converting enzyme inhibitors and angiotensin- II receptor blockers (or angiotensin receptor blockers) and the following generic names of individual agents in current practice: candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan.

Study selection: The authors reviewed all titles and abstracts from the results of our computerized search. We also went into the related links of all relevant articles. In addition to our computerized search, we manually reviewed the reference list of all retrieved articles to complete our search. Study selection process is outlined in figure 1.

Inclusion Criteria: All studies had to meet all the following criteria to be included in the analysis:

1. Randomized controlled trial design.

2. Include patients with HF-PEF.

3. Compare RASI therapy with placebo group.

4. Report at least one of the outcomes: all cause mortality, cardiovascular mortality, worsening of heart failure, hospitalizations for heart failure, worsening of renal function, incidence of hyperkalemia, exercise tolerance on six minute walk test, and quality of life index.

Exclusion Criteria: Studies that did not meet the above criteria were excluded.

Data abstraction: After identifying all relevant articles, we extracted characteristics of the study (author, year, design, duration, sample size, RASIs used, total mortality, cardiovascular mortality, bleeding complications and follow up percentage) and participants (age, gender). Two reviewers independently extracted data and assessed outcomes. The inter-rater agreement was 90%, and disagreements were resolved by consensus.

Quality Assessment

All the trials reported adequate concealment of the randomized treatment sequence. In all studies, follow-up was more than 90% complete.

Outcome Definitions

The definitions of endpoints were as used in individual trials. These are described below. Heart failure with preserved left ventricular ejection fraction was defined as LVEF [greater than or equal to] 45% (I-Preserve), LVEF [greater than or equal to] 40% (CHARM-Preserved), LVEF [greater than or equal to] 45 %>(Enalapnl), LVEF > 45% (Hongkong Study), LVEF > 45% (PEP CHF), LVEF [greater than or equal to] 40% (Valsartan Study).

Worsening of heart failure was defined based on clinical criteria and / or echocardiographic criteria [24-26]. Worsening of renal function was defined as doubling serum creatinine from the baseline [25,26]. A cut off value of potassium more than 6 mmol/L was taken to define presence of hyperkalemia [25,26]. Quality of life (QOL) was assessed using the Minnesota Heart Failure Symptom Questionnaire [27-29], which has been previously validated [18,19]. Exercise tolerance was measured using the Six minute walk distance test (6MWDT) with two baseline tests according to previously defined protocol by Yusuf et al in heart failure trial using exercise endpoints [20].

Statistical analysis: The statistical analysis was performed by the Comprehensive Meta-Analysis software package (version CM 2.2, Biostat, Englewood, NJ). Heterogeneity of the studies was analyzed by the Cochran's Q statistics for each outcome. A systematic review of the literature revealed four eligible studies. As the studies were homogenous for all efficacy outcomes (p<0.05), the combined relative risks (RR) across all the studies and the 95% confidence intervals were computed using the Mantel-Haenszel fixed effect model. For safety outcomes, studies were heterogeneous, so random effect model was used. For quality of life and exercise tolerance, standard difference in means was used to evaluate the treatment effect. A two-sided alpha error of less than 0.05 was considered to be statistically significant.

Results

Literature search

A total of 167 articles were identified of which 31 were potentially relevant studies and screened for retrieval. After title and abstract screening 10 studies were excluded and remaining 21 studies were retrieved for a more detailed evaluation. Out of these 21 studies, 15 were excluded as they did not meet inclusion criteria [did not have control groups, three studies had different end points [21-23] or study population was different. Thus, six trials were included in the final analysis [24-29]. For the purpose of this meta-analysis, HongKong study was further classified in two substudies like HongKong ARB (Diuretics vs Irbesartan) and HongKong ACE (Diuretics vs Ramipril) [27] were considered separately for the purpose of this meta-analysis. Therefore, further description will refer to seven randomized controlled trials in this article.

Overview of study and patient characteristics

Study design was similar in five trials, comparison between a placebo arm and a treatment arm with either an ACE inhibitor (perindopril in PEP-CHF and enalapril in Enalapril study) or ARB (irbesartan in IPRESERVE, candesartan in CHARM Preserved and valsartan in Valsartan study). In HongKong substudies, comparison between a placebo arm (Diuretics) and a treatment arm with either an ACE inhibitor (Ramipril) or ARB (Irbesartan). The characteristics of included trials are mentioned in table 1.

End points

Out of seven, five trials [24-27] included in the study had total and cardiovascular mortality events as their end point. Three trials looked at worsening of heart failure and hospitalizations for heart failure [24-26]. Four trials had quality of life index and exercise tolerance as measured by distance walked in six minute walk test as one of their end points [27-29]. Only two trials had safety events as one of their end points which were worsening of renal functions and incidence of hyperkalemia [25,26].

Clinical Outcomes

The trials included in this meta-analysis consisted of a total of 8425 patients (Placebo group, n=4219; Treatment group, n=4206). The results of current meta-analysis are shown in figures 2-5 and summary of findings given in figure 6.

Total and cardiovascular mortality

Overall there were a total of 1478 [17.54%] deaths of which 746 [17.73%] were in RASI therapy group while 732 [17.35%] in the placebo group. There was no total or cardiovascular mortality noticed in one study [29]. The risk of both total mortality and cardiovascular mortality was similar in placebo and RASI therapy groups [Total Mortality OR: 1.07, CI: 0.96-1.19; p=0.19] or cardiovascular mortality [OR: 1.01, CI: 0.891.15; p = 0.84] [Fig 2].

Worsening and hospitalizations for heart failure

A total of 1317 [15.63%] worsening HF events occurred of which 618 [14.69%] were in RASI therapy group while 699 [16.56%] in the placebo group. There was significant reduction in worsening of heart failure events [OR: 1.16, CI: 1.03-1.31; p<0.05] with RASIs compared to placebo group.

There were total of 1685 [20.54%] hospitalizations for HF of which 807 [19.67%] were in RASI therapy group while 878 [21.40%] in the placebo group. There was a tendency toward reduced hospitalizations due to heart failure events in RASI therapy group [OR: 1.11, CI: 0.99-1.24; p=0.052] but it could not achieve statistical significance [Figure 3].

Quality of life and exercise tolerance

Treatment with RASI lead to significant improvement in six minute walking distance [Standard difference in means: 0.340, CI: 0.181-0.499; p<0.001] and quality of life score in RASIs group [Standard difference in means: -0.308, CI: -0.503 to -0.113; p=0.002] [Figure 4].

Safety Analysis

Overall there were a total of 52 [0.72%] hyperkalemic events of which 34 [0.9%] were in RASI therapy group while 18 [0.5%] in the placebo group. Safety analysis, as expected, revealed significantly more hyperkalemic events [OR: 0.53, CI: 0.29-0.95; p<0.05] and worsening of renal failure [OR: 0.65, CI: 0.50-0.85; p<0.05] in RASI group as compared to placebo group [Figure 5].

Discussion

Our meta-analysis indicates that RASIs therapy in patients with HF-PEF does not alter the total or cardiovascular mortality but it does lead to significant reduction in the worsening of heart failures and hospitalization for heart failure events. Moreover, this analysis shows that RASI therapy in HF-PEF improves the quality of life and improves exercise tolerance. This is an important finding, as it indicates the potential benefit of RASI therapy in reducing the morbidity in this particular group of patients and may have implications for reducing the health care related costs due to recurrent hospitalizations and office visits. With more than 5 million prevalent cases and nearly 1 million hospital discharges yearly, heart failure (HF) represents a rapidly growing therapeutic challenge for health care providers [30]. Risk factors for HFPEF include increasing age, female gender, hypertension, diabetes, obesity, coronary artery disease, and chronic kidney disease [31]. Like systolic heart failure, HFPEF is associated with considerable morbidity and mortality [32] and the risk of adverse outcome increases with the severity of diastolic dysfunction [33].

Inhibition of the Rennin Angiotensin System (RAS) is an integral component of the modern management of HF with LV systolic dysfunction. Current guidelines for the management of chronic heart failure considers initiation and maintenance of ACE inhibition or angiotensin-receptor blockade a class I indication in patients with HF and reduced LV function [34]. However, given the lack of randomized trials investigating modes of therapy for HF-PEF, only control of traditional cardiovascular risk factors is recommended.

Exact pathophysiological mechanism remains unclear, HF-PEF is most often associated with abnormal diastolic function [35,36] and manifestations of activated renin-angiotensin aldosterone system (RAAS), including hypertension, LV hypertrophy, myocardial fibrosis, and vascular dysfunction [37]. Patients with HFPEF have increased activation of RAAS, which contributes to the pathogenesis and progression of the condition [38]. Sustained RAS activation has been implicated in progressive ventricular hypertrophy and myocardial fibrosis, [39-41] both of which may be important contributors to the pathogenesis of diastolic dysfunction and RAS inhibition has been shown to be beneficial in a population of patients with vascular disease [42]. ACE inhibitors and ARBs have demonstrated beneficial effects in animal models of HFPEF [43,44]. Therapy targeted at RAS inhibition results in a significant reduction in neurohormone levels, attenuation of LV remodeling, and decreased HF morbidity and mortality [45-47].

Previous meta-analysis by Shah et al [48] showed reduction in hospitalization but inclusion of three newer trials in our analysis makes our results more robust and relevant to current clinical practice. We also analyzed the impact of RASIs therapy on quality of life and exercise tolerance, which are critically important issues from patient's perspective and from economic perspective. This has not been analysed in previous analysis.

As expected, there were more events of worsening of renal function and hyperkalemia in RASIs therapy group. However, they did not lead to increased hospitalizations or mortality. Thus, overall implication of our results is that by close monitoring of these patients on RASIs therapy, a reduction in hospitalizations and improvement in quality of life can be achieved. Whether this leads to improvement in long-term mortality remains to be investigated. There are various possible explanations for lack of mortality benefit with RASIs therapy in patients with HF-PEF including differential effects according to stage of disease, and role of non-myocardial factors (central aortic stiffness, renal dysfunction) in pathogenesis of diastolic dysfunction. Moreover, recent data indicates equivalent efficacy of RAS-based and nonRAS based approaches for control of blood pressure for improvement of diastolic function [49] highlighting that control of blood pressure, rather than the choice of agent, may be the most important aspect of effective medical therapy.

As with any meta-analysis, one of the limitations of our study is the difference in the definitions of the end points in the component trials, such as the definition of definition of worsening of HF and Cut off value taken for LVEF to define heart failure with preserve ejection fraction was different in various studies. Similarly, baseline characteristics between the 2 groups cannot be compared completely in most meta-analyses because of differences in the study protocols across the component trials. In addition, there is a potential for publication bias but the trials in our analysis had different results and it should reduce this potential risk. In addition, many of these trials were small trials with limited ability to assess clinical outcomes.

Conclusion

RASIs treatment in heart failure with preserve ejection fraction patients showed significant improvement in six minute walking distance, quality of life and significant reduction in worsening heart failure events but failed to reduce total and cardiovascular mortality [Figure 6].

Funding / Support

"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."

[FIGURE 1 OMITTED]

[FIGURE 2 OMITTED]

[FIGURE 3 OMITTED]

[FIGURE 4 OMITTED]

[FIGURE 5 OMITTED]

[FIGURE 6 OMITTED]

References

[1.] Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387-93.

[2.] Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351(11):1097-105.

[3.] Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002;39(1):138-41.

[4.] Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202.

[5.] Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76-84.

[6.] Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9.

[7.] Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948-55.

[8.] Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation. 1990;81(2 Suppl):III48-53.

[9.] Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137(8):631-9.

[10.] MacCarthy PA, Kearney MT, Nolan J, Lee AJ, Prescott RJ, Shah AM, Brooksby WP, Fox KA. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ. 2003;327(7406):78-9.

[11.] Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41(9):1510-8.

[12.] Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-9.

[13.] Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38(5):1277-82.

[14.] Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41-6.

[15.] Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71(7):602-4.

[16.] Hayashida W, Van Eyll C, Rousseau MF, Pouleur H. Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: modification by long-term enalapril treatment. The SOLVD Investigators. J Am Coll Cardiol. 1993;22(5):1403-10.

[17.] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354(9193):1896-1900.

[18.] Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure: content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198-209.

[19.] Sanderson JE, Chan SKW, Yip G, et al. Beta blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8.

[20.] Yusuf S, Ysuyuki R. Using exercise endpoints in heart failure trials: design considerations. Eur Heart J 1996;17:4-6.

[21.] Cuocolo A, Storto G, Izzo R, Iovino GL, Damiano M, Bertocchi F, Mann J, Trimarco B. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 1999;17:17591766.

[22.] Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourciere Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007;369:2079-2087.

[23.] Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensinconverting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006 Mar 27;166(6):659-66.

[24.] Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27: 2338e45.

[25.] Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al, for the CHARM Investigators and Committees. Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction (CHARM Preserved) trial. Lancet 2003;362:777e81.

[26.] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al, for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456e67.

[27.] Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008 May;94(5):573-80. Epub 2008 Jan 20.

[28.] Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010 Jul 1;3(4):477-85. Epub 2010 Jun 1.

[29.] Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD, MacDonald TM. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail. 2009 Oct;11(10):980-9.

[30.] Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statisticsd2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25ee146.

[31.] Chinnaiyan KM, Alexander D, Maddens M, McCullough PA. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J 2007;153:189-200.

[32.] Aurigemma GP. Diastolic heart failure-a common and lethal condition by any name. N Engl J Med 2006;355:308-310.

[33.] Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007;49:687-694.

[34.] Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977e2016.

[35.] Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101(17): 2118-2121.

[36.] Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104(7):779-782.

[37.] Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis. 2005; 47(6):357-366.

[38.] Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich) 2005;7:740-747.

[39.] McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98: 2765e73.

[40.] Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Am Coll Cardiol 1998;30:475e83.

[41.] Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865e79.

[42.] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardio vascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000;342:145e53.

[43.] Yamamoto E, Kataoka K, Shintaku H, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol 2007;27:2569-2575.

[44.] Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103: 148-154.

[45.] Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, et al, and the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 1995;75:1151e7.

[46.] Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993;88:2277e83.

[47.] Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993;22:146Ae153.

[48.] Shah RV, Desai AS, Givertz MM. The Effect of Renin-Angiotensin System Inhibitors on Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. J Cardiac Fail 2010;16:260-267.

[49.] Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007;369:2079e87.

Mukesh Singh *, Tejaskumar Shah, Sasikanth Adigopula, Sandeep Khosla, Rohit Arora, Evyan Jawad

Department of Cardiology, Chicago Medical School, United States

* Corresponding author; Email: drmukeshsingh@yahoo.com
Table 1: Study characteristics

                       Study Population
Trial         Design   (Placebo)                   RASI

PEP-CHF       RCT      NYHA III-IV-26%; LVEF-      Perindopril
                       64%, HTN -79%; Ischemic-
                       -26%

CHARM         RCT      White-92.3%                 Candesartan
PRESERVED              NYHA III/IV--40%
                       LVEF--54.1%, HTN
                       --23%, Ischemic--
                       56.5%

ENALAPRIL     RCT      White-94% NYHA III-         Enalapril
                       IV--25% LVEF--60%, HTN--
                       75%; Ischemic--NR

I-PRESERVED   RCT      White--94% NYHA III-        Irbesartan
                       IV--80% LVEF--65%, HTN -
                       64%; Ischemic--26%

Hongkong      RCT      NYHA III-IV--28% LVEF--     Diuretics vs
ARB                    69%, HTN -76%; Ischemic-    Irbesartan
                       -18%

Hongkong                                           Diuretics vs
ACEI                                               Ramipril

Valsartan     RCT      White--93.9%                Valsaratan
                       NYHA III/IV--NR
                       LVEF--71.52%
                       HTN--89%, Ischemic
                       NR

               Number of subjects
Trial         Placebo      Control     Follow up (months)

PEP-CHF          426          424             26.2

CHARM            1514        1509             36.6
PRESERVED

ENALAPRIL         36          35              49.5

I-PRESERVED      2061        2067              50

Hongkong          50          56               12
ARB

Hongkong          50          45
ACEI

Valsartan         82          70              3.5

Trial         End points studied

PEP-CHF       All causes death, CV
              mortality Hospitalization
              for HF, Worsening HF

CHARM         CV mortality, Worsening
PRESERVED     HF, Hospitalization for
              HF, Non fatal MI, Non
              fatal Stroke

ENALAPRIL     Six MWDT, Quality of Life.

I-PRESERVED   Death any causes, Death
              due to HF, Death--CV
              Causes, Hospitalization
              for CV causes, Worsening
Hongkong      Six MWDT, Readmission HF,
ARB           CV--Death, Other Causes
              Death, Change QOL

Hongkong
ACEI

Valsartan     Exercise time

ARB = Angiotensin Receptor Blocker; ACEI = Angiotensin Converting
Enzyme Inhibitor; RCT = Randomized control Trial; NR = Not Reported;
NYHA = New York Heart Association; LVEF = Left Ventricular Ejection
Fraction; HTN = Hypertension; CV = Cardiovascular; HF = Heart
Failure; MI = Myocardial Infarction; MWDT = Minutes Walk Distance
Test; QOL= Quality of Life
COPYRIGHT 2011 DRUNPP
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Author:Singh, Mukesh; Shah, Tejaskumar; Adigopula, Sasikanth; Khosla, Sandeep; Arora, Rohit; Jawad, Evyan
Publication:International Journal of Collaborative Research on Internal Medicine & Public Health (IJCRIMPH)
Article Type:Report
Geographic Code:1USA
Date:Apr 1, 2011
Words:4521
Previous Article:Effect of Bacopa monnieri on cognitive functions in Alzheimer's disease patients.
Next Article:Self-reported chronic somatic diseases among adolescent students in Mansoura, Egypt.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters